menu
    • menu
    [{"orgOrder":0,"company":"Aelis Farma","sponsor":"National Institute on Drug Abuse | Columbia University | New York State Psychiatric Institute | ClinStar","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ National Institute on Drug Abuse | Columbia University | New York State Psychiatric Institute | ClinStar","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ National Institute on Drug Abuse | Columbia University | New York State Psychiatric Institute | ClinStar"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Undisclosed"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Aelis Farma \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Aelis Farma \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Undisclosed"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Aelis Farma","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Aelis Farma"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AEF0217","moa":"GABAA-alpha-5 receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aelis Farma \/ European Commission","highestDevelopmentStatusID":"7","companyTruncated":"Aelis Farma \/ European Commission"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AEF0217","moa":"GABAA-alpha-5 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aelis Farma \/ European Commission","highestDevelopmentStatusID":"6","companyTruncated":"Aelis Farma \/ European Commission"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Aelis Farma \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"Aelis Farma \/ National Institute on Drug Abuse"}]

    Find Clinical Drug Pipeline Developments & Deals by Aelis Farma

    Menu

    Aelis Farma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Indivior

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indivior Updates Aelis Farma's Phase 2B Results for Cannabis Use Disorder

                            Details : AEF0117 is an oral drug candidate, being evaluated for its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 04, 2024

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Indivior

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-Drug Interaction Between THC and AEF0117

                            Details : 3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Marijuana Abuse.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 02, 2024

                            Lead Product(s) : 3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEF0217

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : European Commission

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome

                            Details : AEF0217 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Down Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 28, 2023

                            Lead Product(s) : AEF0217

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : European Commission

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

                            Details : AEF0117 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Marijuana Abuse.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 26, 2022

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers

                            Details : 3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Marijuana Abuse.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 11, 2022

                            Lead Product(s) : 3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Recipient : Indivior

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and T...

                            Details : Following the promising results of a Phase 2a study showing that AEF0117 reduced the subjective effects of cannabis and cannabis self-administration in subjects with moderate to severe CUD.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2022

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Recipient : Indivior

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

                            Details : AEF0117 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Marijuana Abuse.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2022

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEF0217

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : European Commission

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Heal...

                            Details : AEF0217 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 28, 2021

                            Lead Product(s) : AEF0217

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : European Commission

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Indivior

                            Deal Size : $130.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Indivior Extends Leadership Position In Substance Use Disorder Treatment With Exclusive Agreement For Leading ...

                            Details : Indivior has entered into a strategic collaboration with Aelis Farma ("Aelis"), a private biotechnology company based in Bordeaux, France, that includes an exclusive option and license agreement (the "Agreement") for the global rights to AEF0117.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $30.0 million

                            June 08, 2021

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Indivior

                            Deal Size : $130.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed

                            Aelis Farma

                            France arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : National Institute on Drug Abuse | Columbia University | New York State Psychiatric Institute | ClinStar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

                            Details : AEF0117 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Marijuana Abuse.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 24, 2018

                            Lead Product(s) : AEF0117

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : National Institute on Drug Abuse | Columbia University | New York State Psychiatric Institute | ClinStar

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth